Framingham Risk Score Assessment in Subjects with Pre-diabetes and Diabetes: A Cross-Sectional Study in Korea

Kwon, Hyuk Sang; Song, Ki Ho; Yu, Jae Myung; Kim, Dong Sun; Shon, Ho Sang; Ahn, Kyu Jeung; Choi, Sung Hee; Ko, Seung Hyun; Kim, Won; Lee, Kyoung Hwa; Nam-Goong, Il Seong; Park, Tae Sun

doi:10.7570/jomes20137

Cited by 4 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipids are considered an essential hazard for the progression of prediabetes into diabetes and combined cardiovascular complications. A non-interventional cross-sectional study conducted in South Korea showed that prediabetes combined with abnormal lipid metabolism (high TG, low HDL-C) was 2.89 times more likely to develop cardiac complications later in life than patients with normal lipid metabolism ( Kwon et al, 2021 ). Therefore, targeted measures should be taken to enhance the management of dyslipidemia in prediabetes.…”

Section: Discussionmentioning

confidence: 99%

Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis

Wang²,

Zhao³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: To compare the clinical efficacy and safety of SIX Traditional Chinese Patent Medicines (TCPM) recommended by guidelines in improving lipids for patients with prediabetes by network meta-analysis.Methods: Randomized controlled trials of 6 TCPM in the treatment of prediabetes were searched systematically in various databases. After extracting effective data, the risk of bias was assessed using Review Manager 5.3 and Cochrane Collaboration Systems Evaluator’s Manual. Network meta-analysis was performed using STATA 15.0 based on the frequency statistical model. The effect size and credibility of the evidence for the intervention were summarized based on a minimal contextualized framework.Results: A total of 27 studies involving 2,227 patients were included. Compared with lifestyle modification (LM), Shenqi + LM [SMD −0.49 (95% CI: −0.85, −0.12)] and Jinqi + LM [SMD −0.44 (95% CI: −0.81, −0.06)] showed statistically significant effect in lowering TG, Shenqi + LM [SMD −0.51 (95%CI: −0.86, −0.17)] and Jinqi + LM [SMD −0.44 (95%CI: −0.80, −0.08)] in lowering TC, Jinlida + LM [SMD −0.31 (95%CI: −0.59, −0.04)] in lowering LDL-C, Shenqi + LM [SMD 0.29 (95%CI: 0.06, 0.51)] and Jinqi + LM [SMD 0.16 (95%CI: 0.01, 0.31)] in increasing HDL-C.Conclusion: For patients with prediabetes, Traditional Chinese patent medicine Jinqi and Shenqi combined with lifestyle modification were associated with a significant reduction in TG and TC, while Shenqi + LM was among the most effective. Jinlida + LM was among the least effective.Systematic Review Registration:https://clinicaltrials.gov/, identifier PROSPERO(CRD42021279332).

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis

Wang²,

Zhao³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Numerous tools are available for assessing cardiovascular risk. The Framingham Heart Study (FHS), one of the well-known cardiovascular riskpredicting models, plays a crucial role in the management of care, evaluation of intervention outcomes, and establishment of risk strati cation [7,8].…”

Section: Introductionmentioning

confidence: 99%

“…The TG/HDL ratio has gained interest as a potential indicator of cardiovascular risk, providing a straightforward and e cient method for initial evaluation. Traditional approaches to risk assessment, including the use of the FHS Cardiovascular Risk Score, are widely applied for predicting CVD risk over the long term [7,8,22,23]. However, including the TG/HDL ratio in these models remains underexplored, especially in individuals with T2DM.…”

Section: Introductionmentioning

confidence: 99%

Triglyceride to High-Density Lipoprotein ratio as a predictor for 10-year cardiovascular disease in individuals with diabetes in Thailand

Poochanasri,

Lertsakulbunlue,

Kookanok

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Cardiovascular disease (CVD) represents a group of disorders affecting the heart and blood vessels. The Framingham Heart Study (FHS) predicted a 10-year CVD risk score is used to establish risk stratification and evaluate intervention outcomes. TG/HDL ratio is utilized as an alternative tool to assess CVD risk. This study, therefore, aims to investigate the role of the TG/HDL ratio in predicting the 10-year cardiovascular risk utilizing the established FHS risk prediction model in individuals with T2DM. Methods A cross-sectional study was conducted among 61,004 patients with T2DM without a history of CVD aged between 30–74 years. From 2014, 2015, and 2018. The predicted 10-year CV risk was calculated using laboratory-based Framingham heart study equations. The cut point of TG/HDL was calculated using Youden’s J statistics of the ROC curve for predicting high predicted 10-year CV risk. Linear and Multivariable logistic regression analyses were performed to investigate the association between TG/HDL and high predicted 10-year CVD risk. Results For the overall participant group, ROC curve analysis yielded an AUC of 0.62 (95% CI 0.61–0.62) for predicting high FHS-CVD risk, with a TG/HDL cutoff value of 3.09 (Sensitivity 61%, Specificity 57%). Linear regression analysis revealed a dose-response relationship between the TG/HDL ratio and log-transformed predicted 10-year CV risk across both sexes and all age groups. Participants with high TG/HDL ratios (> 3.09) were positively associated with a prevalence of high FHS-CVD risk (AOR: 5.91, 95% CI 5.52–6.31). In comparison with participants in the first TG/HDL quartile (< 2.05), those in the fourth quartile (> 4.91) had a higher chance of high predicted 10-year CV risk (AOR: 18.27, 95% CI 16.537–20.185). Subgroup analysis revealed that the strength of association was more intense in females and those of advanced age. Conclusions TG/HDL can be used as a risk factor to determine predicted 10-year CV risk, particularly in individuals with T2DM aged between 30–74 years. However, further study is necessary to robustly establish the association between TG/HDL and cardiovascular disease risk prediction.

show abstract

“…Various CV risk assessment algorithms have been developed, but their applicability to subjects with diabetes is uncertain [ 10 , 11 ]. The Framingham risk score (FRS) is one of the most effective cardiovascular risk calculators used globally in clinical practice to identify and treat high-risk populations and effectively communicate risk [ 12 , 13 ]. In Thailand, although a Thai CV risk score developed based on a specific career population is available, further external validation is still needed [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Trends in predicted 10-year risk for cardiovascular diseases among patients with type 2 diabetes in Thailand, from 2014 to 2018

Lertsakulbunlue

Mungthin

Rangsin

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Cardiovascular diseases (CVD) are the leading causes of death globally, including Thailand. Approximately one-tenth of Thai adults have type 2 diabetes (T2D), a significantly increasing CVD. Our study aimed to determine the trends of predicted 10-year CVD risk among patients with T2D. Methods A series of hospital-based cross-sectional studies were conducted in 2014, 2015 and 2018. We included Thai patients with T2D aged 30–74-year-old without a history of CVD. The predicted 10-year risk for CVD was calculated based on Framingham Heart Study equations both with simple office-based nonlaboratory and laboratory-based. Age- and sex-adjusted means and proportions of predicted 10-year risk for CVD were calculated. Results A total of 84,602 patients with T2D were included in the present study. The average SBP among study participants was 129.3 ± 15.7 mmHg in 2014 and rose to 132.6 ± 14.9 mmHg in 2018. Likewise, the average body mass index was 25.7 ± 4.5 kg/m2 in 2014 and elevated to 26.0 ± 4.8 kg/m2 in 2018. The age- and sex-adjusted mean of the predicted 10-year CVD risk (simple office-based) was 26.2% (95% CI: 26.1–26.3%) in 2014 and rose to 27.3% (95% CI: 27.2–27.4%) in 2018 (p-for trend < 0.001). While the age- and sex-adjusted mean of the predicted 10-year CVD risk (laboratory-based) ranged from 22.4–22.9% from 2014 to 2018 (p-for trend < 0.001). The age- and sex-adjusted prevalence of the high predicted 10-year CVD risk (simple office-based) was 67.2% (95% CI: 66.5–68.0%) in 2014 and significantly rose to 73.1% (95% CI: 72.4–73.7%) in 2018 (p-for trend < 0.001). Nevertheless, the age- and sex-adjusted prevalence of the high predicted 10-year CVD risk (laboratory-based) ranged from 46.0–47.4% from 2014 to 2018 (p-for trend = 0.405). However, among patients with available laboratory results, a significantly positive correlation was noted between predicted 10-year CVD risk, simple office-based and laboratory-based (r = 0.8765, p-value < 0.001). Conclusion Our study demonstrated significant rising trends in the predicated 10-year CVD risk among Thai patients with T2D. In addition, the results empowered further improved modifiable CVD risks, especially regarding high BMI and high blood pressure.

show abstract

Framingham Risk Score Assessment in Subjects with Pre-diabetes and Diabetes: A Cross-Sectional Study in Korea

Cited by 4 publications

References 43 publications

Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis

Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis

Triglyceride to High-Density Lipoprotein ratio as a predictor for 10-year cardiovascular disease in individuals with diabetes in Thailand

Trends in predicted 10-year risk for cardiovascular diseases among patients with type 2 diabetes in Thailand, from 2014 to 2018

Contact Info

Product

Resources

About